Boston Scientific Launches 2.25 mm Promus Coronary Stent

Boston Scientific released its 2.25 mm Promus everolimus-eluting coronary stent system for use in vessels as small as 2.25 mm in diameter. It features a thin-strut, open-cell design to allow for excellent flexibility and conformability in the vessel. The low-profile stent and catheter tip help enhance deliverability, especially in small vessels.

The addition of this stent expands the available size matrix of Boston Scientific's Promus stent portfolio to include diameters from 2.25 to 4 mm and lengths from 8 to 28 mm.

Data from clinical studies have shown that an estimated 10 percent of patients undergoing percutaneous coronary interventions have small vessels (less than 2.5 mm). The 2.25 mm Promus stent joins the 2.25 mm Ion paclitaxel-eluting platinum chromium stent as the company's approved drug-eluting stenting options for small vessels.

The Promus stent is a private-labeled Xience V everolimus-eluting coronary stent System manufactured by Abbott and distributed by Boston Scientific. The stent is sold under the Promus name as part of a 2006 agreement from when Abbott purchased the Xience stent technology from Boston in 2006.

The 2.25 mm version of the stent was cleared by the FDA in May 2011.

For more information: www.bostonscientific.com